Merck
CN

Zinc supplements for preventing otitis media.

The Cochrane database of systematic reviews (2012-04-20)
Anjana Gulani, Harshpal S Sachdev
摘要

Otitis media (OM) is inflammation of the middle ear and is usually caused by infection. It affects people of all ages but is particularly common in young children. Around 164 million people worldwide have long-term hearing loss caused by this condition, 90% of them in low-income countries. As zinc supplements prevent pneumonia in disadvantaged children, we wanted to investigate whether zinc supplements could also prevent OM. To evaluate whether zinc supplements prevent OM in adults and children of different ages. We searched the Cochrane Central Register of Controlled Trials (CENTRAL 2012, Issue 1) which includes the Cochrane Acute Respiratory Infections Groups' Specialised Register, MEDLINE (1950 to February week 1, 2012) and EMBASE (1974 to February 2012). Randomised, placebo-controlled trials of zinc supplements given at least once a week for at least a month for preventing OM. Two review authors independently assessed the eligibility and methodological quality of the included trials and extracted and analysed data. We summarised results using risk ratios (RRs) or rate ratios for dichotomous data and mean differences (MDs) for continuous data. We combined trial results where appropriate. We identified 12 trials for inclusion, 10 of which contributed outcomes data. There was a total of 6820 participants. In trials of healthy children living in low-income communities, two trials did not demonstrate a significant difference between the zinc supplemented and placebo groups in the numbers of participants experiencing an episode of definite OM during follow-up (3191 participants); another trial showed a significantly lower incidence rate of OM in the zinc group (rate ratio 0.69, 95% confidence interval (CI) 0.61 to 0.79, n = 1621). A small trial of 39 infants undergoing treatment for severe malnutrition suggested a benefit of zinc for the mean number of episodes of OM (mean difference (MD) -1.12 episodes, 95% CI -2.21 to -0.03). Zinc supplements did not seem to cause any serious adverse events but a small minority of children were reported to have vomited shortly after ingestion of the supplements. The trial evidence included is generally of good quality, with a low risk of bias. Evidence on whether zinc supplementation can reduce the incidence of OM in healthy children under the age of five years living in low- and middle-income countries is mixed. There is some evidence of benefit in children being treated for marasmus (severe malnutrition) but this is based on one small trial and should therefore be treated with caution.

材料
货号
品牌
产品描述

Sigma-Aldrich
醋酸锌 二水合物, ACS reagent, ≥98%
Sigma-Aldrich
葡萄糖酸钠, meets USP testing specifications
Sigma-Aldrich
醋酸锌 二水合物, puriss. p.a., ACS reagent, ≥99.0% (KT)
Sigma-Aldrich
醋酸锌 二水合物, reagent grade
Sigma-Aldrich
醋酸锌 二水合物, 99.999% trace metals basis
Sigma-Aldrich
葡萄糖酸 溶液, 49-53 wt. % in H2O
Sigma-Aldrich
D -葡萄糖酸 钠盐, ≥99%
Sigma-Aldrich
葡萄糖酸钾, ≥99% (HPLC)
Sigma-Aldrich
葡萄糖酸钾, 97.0-103.0% dry basis, meets USP testing specifications
Supelco
葡萄糖酸钾, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
D-葡萄糖酸亚铁盐 二水合物, 98%
Sigma-Aldrich
葡萄糖酸镁 水合物, ≥98% (HPLC)
Sigma-Aldrich
醋酸锌 二水合物, puriss., E 650, 99-102%
Supelco
D -葡萄糖酸 钠盐, certified reference material, TraceCERT®, Manufactured by: Sigma-Aldrich Production GmbH, Switzerland
Sigma-Aldrich
葡萄糖酸镁 水合物, 98.0-102% anhydrous basis, meets USP testing specifications